For a patient with hypertrophic cardiomyopathy, which therapeutic intervention is commonly advised?

Choice A rationale Beta-blockers are the primary pharmacological treatment for symptomatic hypertrophic cardiomyopathy because they reduce the heart rate and the force of contraction. By slowing the heart rate, they extend the diastolic filling time, which allows more blood to enter the stiffened left ventricle. This reduces the outflow tract obstruction and decreases myocardial oxygen demand. Maintaining a lower heart rate helps prevent symptoms like chest pain and syncope, while also protecting the patient from exercise-induced arrhythmias and sudden cardiac death. Choice B rationale Daily aspirin is typically used for primary or secondary prevention of atherosclerotic cardiovascular disease to prevent platelet aggregation in the coronary arteries. Hypertrophic cardiomyopathy is a structural and genetic muscle disorder, not primarily an obstructive coronary artery disease. While some patients might take aspirin for other reasons, it does not address the underlying pathophysiology of ventricular hypertrophy or outflow tract obstruction. Treatment focus for this condition is on improving ventricular filling and reducing the pressure gradient across the aortic valve. Choice C rationale High-intensity exercise is strictly contraindicated for patients with hypertrophic cardiomyopathy. The structural abnormalities of the heart muscle and the potential for outflow tract obstruction significantly increase the risk of sudden cardiac arrest during strenuous physical exertion. Intense activity can trigger lethal ventricular arrhythmias or a sudden drop in cardiac output. Patients are usually advised to stick to low-to-moderate intensity activities and must avoid competitive sports to ensure their safety and prevent excessive stress on the hypertrophied myocardium. Choice D rationale There is no specific evidence suggesting that a diet high in potassium provides therapeutic benefits for hypertrophic cardiomyopathy. While maintaining normal electrolyte balance is important for all cardiac patients to prevent arrhythmias, increasing potassium intake beyond the normal physiological range of 3.5 to 5.0 mEq/L does not treat muscle hypertrophy. Management instead focuses on maintaining adequate hydration to ensure sufficient preload and using medications that optimize the mechanical function of the left ventricle and reduce the risk of obstruction.